Gene editing therapy for cardiovascular diseases

被引:0
作者
Wu, Xinyu [1 ,2 ]
Yang, Jie [1 ,2 ]
Zhang, Jiayao [1 ,2 ]
Song, Yuning [1 ,2 ]
机构
[1] Jilin Univ, State Key Lab Diag & Treatment Severe Zoonot Infec, Key Lab Zoonosis Res, Minist Educ, Changchun, Peoples R China
[2] Jilin Univ, Coll Vet Med, Changchun, Peoples R China
来源
MEDCOMM | 2024年 / 5卷 / 07期
关键词
cardiovascular disease; CRISPR/Cas; gene therapy; lipid nanoparticles; MITOCHONDRIAL GENOMES; DIRECTED EVOLUTION; IMMUNE-SYSTEM; DNA CLEAVAGE; MOUSE MODEL; CRISPR; RNA; BASE; BACTERIAL; EFFICIENT;
D O I
10.1002/mco2.639
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The development of gene editing tools has been a significant area of research in the life sciences for nearly 30 years. These tools have been widely utilized in disease detection and mechanism research. In the new century, they have shown potential in addressing various scientific challenges and saving lives through gene editing therapies, particularly in combating cardiovascular disease (CVD). The rapid advancement of gene editing therapies has provided optimism for CVD patients. The progress of gene editing therapy for CVDs is a comprehensive reflection of the practical implementation of gene editing technology in both clinical and basic research settings, as well as the steady advancement of research and treatment of CVDs. This article provides an overview of the commonly utilized DNA-targeted gene editing tools developed thus far, with a specific focus on the application of these tools, particularly the clustered regularly interspaced short palindromic repeat/CRISPR-associated genes (Cas) (CRISPR/Cas) system, in CVD gene editing therapy. It also delves into the challenges and limitations of current gene editing therapies, while summarizing ongoing research and clinical trials related to CVD. The aim is to facilitate further exploration by relevant researchers by summarizing the successful applications of gene editing tools in the field of CVD. The application of the CRISPR/Cas system for gene editing therapy in CVDSeveral gene editing systems have been utilized to target crucial genes associated with cardiovascular disease in different animal models through diverse delivery methods, all of which have displayed encouraging outcomes. Recent clinical trials have showcased notable advancements in multiple gene editing therapeutic strategies for cardiovascular disease. Both preclinical and clinical gene editing therapies for cardiovascular diseases establish a strong groundwork for further research and the development of novel therapeutic interventions for cardiovascular diseases image .
引用
收藏
页数:31
相关论文
共 256 条
[11]   Search-and-replace genome editing without double-strand breaks or donor DNA [J].
Anzalone, Andrew V. ;
Randolph, Peyton B. ;
Davis, Jessie R. ;
Sousa, Alexander A. ;
Koblan, Luke W. ;
Levy, Jonathan M. ;
Chen, Peter J. ;
Wilson, Christopher ;
Newby, Gregory A. ;
Raguram, Aditya ;
Liu, David R. .
NATURE, 2019, 576 (7785) :149-+
[12]   11 clinical trials that will shape medicine in 2024 [J].
Arnold, Carrie ;
Webster, Paul .
NATURE MEDICINE, 2023, 29 (12) :2964-2968
[13]   MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation [J].
Bacman, Sandra R. ;
Kauppila, Johanna H. K. ;
Pereira, Claudia, V ;
Nissanka, Nadee ;
Miranda, Maria ;
Pinto, Milena ;
Williams, Sion L. ;
Larsson, Nils-Goeran ;
Stewart, James B. ;
Moraes, Carlos T. .
NATURE MEDICINE, 2018, 24 (11) :1696-+
[14]   Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs [J].
Bacman, Sandra R. ;
Williams, Sion L. ;
Pinto, Milena ;
Peralta, Susana ;
Moraes, Carlos T. .
NATURE MEDICINE, 2013, 19 (09) :1111-1113
[15]   Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins [J].
Banskota, Samagya ;
Raguram, Aditya ;
Suh, Susie ;
Du, Samuel W. ;
Davis, Jessie R. ;
Choi, Elliot H. ;
Wang, Xiao ;
Nielsen, Sarah C. ;
Newby, Gregory A. ;
Randolph, Peyton B. ;
Osborn, Mark J. ;
Musunuru, Kiran ;
Palczewski, Krzysztof ;
Liu, David R. .
CELL, 2022, 185 (02) :250-+
[16]   CRISPR provides acquired resistance against viruses in prokaryotes [J].
Barrangou, Rodolphe ;
Fremaux, Christophe ;
Deveau, Helene ;
Richards, Melissa ;
Boyaval, Patrick ;
Moineau, Sylvain ;
Romero, Dennis A. ;
Horvath, Philippe .
SCIENCE, 2007, 315 (5819) :1709-1712
[17]  
Bibikova M, 2002, GENETICS, V161, P1169
[18]   Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system [J].
Bikard, David ;
Jiang, Wenyan ;
Samai, Poulami ;
Hochschild, Ann ;
Zhang, Feng ;
Marraffini, Luciano A. .
NUCLEIC ACIDS RESEARCH, 2013, 41 (15) :7429-7437
[19]   T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].
BLAESE, RM ;
CULVER, KW ;
MILLER, AD ;
CARTER, CS ;
FLEISHER, T ;
CLERICI, M ;
SHEARER, G ;
CHANG, L ;
CHIANG, YW ;
TOLSTOSHEV, P ;
GREENBLATT, JJ ;
ROSENBERG, SA ;
KLEIN, H ;
BERGER, M ;
MULLEN, CA ;
RAMSEY, WJ ;
MUUL, L ;
MORGAN, RA ;
ANDERSON, WF .
SCIENCE, 1995, 270 (5235) :475-480
[20]   Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors [J].
Boch, Jens ;
Scholze, Heidi ;
Schornack, Sebastian ;
Landgraf, Angelika ;
Hahn, Simone ;
Kay, Sabine ;
Lahaye, Thomas ;
Nickstadt, Anja ;
Bonas, Ulla .
SCIENCE, 2009, 326 (5959) :1509-1512